MARKET

KPTI

KPTI

Karyopharm Therapeutics Inc
NASDAQ
1.150
+0.015
+1.32%
After Hours: 1.200 +0.05 +4.35% 19:19 05/17 EDT
OPEN
1.150
PREV CLOSE
1.135
HIGH
1.190
LOW
1.125
VOLUME
1.56M
TURNOVER
0
52 WEEK HIGH
2.670
52 WEEK LOW
0.6174
MARKET CAP
135.37M
P/E (TTM)
-0.9017
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at KPTI last week (0506-0510)?
Weekly Report · 05/13 09:06
Buy Rating for Karyopharm Therapeutics: Debt Restructuring and Promising Xpovio Studies Drive Optimistic Outlook
TipRanks · 05/10 05:41
Maintaining Hold on Karyopharm: A Balancing Act Between Financial Restructuring and Clinical Milestones
TipRanks · 05/10 05:32
Karyopharm Therapeutics Inc. Quarterly Report for the Quarter Ended March 31, 2024
Press release · 05/09 15:48
Karyopharm Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Karyopharm Therapeutics reported disappointing results for the first quarter of 2024. The company's shares are down 5.6% from a week ago. Revenue missed analyst estimates by 3.9%. Earnings per share exceeded estimates by 7.9% and is forecast to grow 23% in the next 3 years. Simply Wall St finds 5 warning signs for Karyophar Therapeutic.
Simply Wall St · 05/09 12:30
Karyopharm Therapeutics Price Target Maintained With a $8.00/Share by HC Wainwright & Co.
Dow Jones · 05/09 11:03
HC Wainwright & Co. Reiterates Buy on Karyopharm Therapeutics, Maintains $8 Price Target
Benzinga · 05/09 10:53
Karyopharm Therapeutics (KPTI) Gets a Buy from RBC Capital
TipRanks · 05/09 10:50
More
About KPTI
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. It is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, mycosis fungoides (MF) and diffuse large B-cell lymphoma (DLBCL). The Company’s product candidate, eltanexor, oral SINE compound that, like selinexor, selectively blocks the nuclear export protein XPO1.

Webull offers Karyopharm Therapeutics Inc stock information, including NASDAQ: KPTI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KPTI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KPTI stock methods without spending real money on the virtual paper trading platform.